EWOLUTION: Outcomes of left atrial appendage closure in the real world

Original Title: EWOLUTION: 3-months outcome of Left Atrial Appendage Closure with the WATCHMAN device in Europe.
Presenter: Martin Bergmann.

 

This study presented the experience of left atrial appendage closure with the WATCHMAN device outside the selected population of prior randomized clinical trials. The study included more than 1000 patients in this single arm multicenter registry; 39% of these patients had high bleeding risk or had a history of bleeding.
Implantation success was 98.5% in cases with high adverse events rate or 3.2% death rate. Regarding major bleeding, stroke or procedure/device related event, there were no significant differences in drug regime in the first 3 months after implantation.

 

Conclusion
The left atrial appendage closure device WATCHMAN showed a high success rate and low periprocedural complications rate despite the high bleeding risk of the population involved. Bleeding was the most common event in the first three months and there were no differences in DAPT or new anticoagulants in this period.

 

Ewolution

More articles by this author

TAVI at 10 Years: First Study to Assess TAVI Long Term Durability

Original Title: First look at long-term durability of transcatheter heart valves: Assessment of valve function up to 10 years after implantation. Presenter: Danny Dvir.   Transcatheter aortic...

OPINON: OCT vs. IVUS Guided PCI

Original Title: Optical frequency domain imaging vs. IVUS in PCI: the OPINION trial – one-year primary endpoint results. Presenter: T. Kubo.   Optical coherence tomography (OCT) is...

LEADERS FREE ACS: Biolimus coated stent vs. bare metal stent in ACS with high bleeding risk

Original Title: Biolimus A9 drug-coated stent vs. bare metal stent in patients presenting with ACS. A pre-specified LEADERS FREE ACS sub-study. Presenter: C.K. Naber.   In ACS...

FANTOM II: New sirolimus eluting bioresorbable scaffold

Original Title: Fantom sirolimus-eluting BRS – FANTOM II Trial. Presenter: Alexandre Abizaid   This new sirolimus eluting bioresorbable scaffold is the only one which can be directly...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Valve-in-Valve in Small Surgical Aortic Bioprostheses: Balloon-Expandable or Self-Expanding? Three-Year Results from the LYTEN Trial

Dysfunction of small surgical aortic bioprostheses represents a challenging scenario for transcatheter aortic valve replacement in the valve-in-valve setting, due to the higher incidence...

AHA/ACC Guideline on the Management of Acute Pulmonary Embolism 2026

The 2026 ACC/AHA guideline for the management of acute pulmonary embolism (PE) introduces a conceptual shift by replacing the traditional “risk-based” classification with an...

How real are the adverse effects of statins? Evidence from randomized clinical trials

The safety of statins continues to be a subject of debate, partly due to the extensive list of adverse effects included in prescribing information,...